Basic information Safety Supplier Related

3-azaspiro[5.5]undecane hydrochloride

Basic information Safety Supplier Related

3-azaspiro[5.5]undecane hydrochloride Basic information

Product Name:
3-azaspiro[5.5]undecane hydrochloride
Synonyms:
  • 3-azaspiro[5.5]undecane hydrochloride
  • 4,4-Pentamethylenepiperidine
  • 9-azaspiro[5.5]undecane chloride
  • 3-Azaspiro[5.5]undecane HCl
  • 4,4-Pentamethylenepiperidine HCl
  • hydrochloride - [A81406]
CAS:
1125-01-5
MF:
C10H20ClN
MW:
189.7255
EINECS:
214-404-1
Product Categories:
  • Heterocycles
  • Inhibitors
Mol File:
1125-01-5.mol
More
Less

3-azaspiro[5.5]undecane hydrochloride Chemical Properties

storage temp. 
Inert atmosphere,Room Temperature
solubility 
Soluble to 100 mM in water and to 100 mM in DMSO
form 
Powder
color 
White to off-white
More
Less

3-azaspiro[5.5]undecane hydrochloride Usage And Synthesis

Uses

4,4-Pentamethylenepiperidine Hydrochloride is a M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2).

Uses

A M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2).

Synthesis

1130-32-1

1125-01-5

The synthesis of BL-1743 started with 3,3-cyclopentane glutarimide, which was first subjected to a reductive reaction with lithium aluminum hydride (LiAlH4) in tetrahydrofuran (THF) under refluxing conditions to afford 3-azaspiro[5,5]undecane hydrochloride (9), which was followed by treatment with HCl/ethyl ether to obtain the target product in 75% yield (see Scheme 1). Next, model compound BL-1743 was prepared by nucleophilic substitution of compound 9 by 2-methylthio-2-imidazoline.In addition, compound 9 was subjected to reductive amination with different aldehydes in dichloroethane using sodium triacetoxyborohydride (NaBH(OAc)3) and formic acid (HCO2H) as reducing agents to afford derivatives 1-8 in yields ranging from 65% to 95%. The results of activity tests showed that the inhibitory activity of BL-1743 was completely lost at 100 μM concentration after the imidazoline ring was replaced by a hydrophobic substituent or a heterocyclic ring that lacked a hydrogen bond donor (HBD), and the AM2 activity remained >90%. In contrast, inhibitors 7 and 8 containing an imidazole head group showed moderate inhibitory activity, suggesting that the presence of a hydrogen bond donor may be a structural feature necessary for inhibitory activity.

References

[1] Patent: US2010/69420, 2010, A1. Location in patent: Page/Page column 7

3-azaspiro[5.5]undecane hydrochlorideSupplier

J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
Capot Chemical Co., Ltd
Tel
+86 (0) 571 85 58 67 18
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Shanghai Balmxy Pharmaceutical Co., Ltd
Tel
021-24206007 13764915196
Email
sales@balmxy.com